Gilead Sciences (GILD) just cleared an important milestone: its once daily bictegravir and lenacapavir combo matched Biktarvy ...
Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling ...
Gilead Sciences said on Monday its experimental HIV treatment met the main goal and was found to be statistically ...
With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...
Gilead Sciences said its in-development HIV treatment met the primary endpoint of a recent late-stage clinical trial. The biopharmaceutical company said Monday that the treatment, a once-daily single ...
Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.
Investigational Treatment Regimen Could Expand Options for Virologically Suppressed Adults –– Positive Phase 3 Results from ...
Gilead's ARTISTRY-2 trial shows BIC/LEN is non-inferior to Biktarvy in virologically suppressed adults with HIV, with no new safety signals. ARTISTRY-2's design involved a randomized, double-blind ...
(Reuters) -Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries if it wins U.S. approval despite funding uncertainty over the ...
The Food and Drug Administration on Wednesday approved Gilead's twice-yearly antiviral injection for preventing HIV — a milestone that the company and some experts say could help bring the world ...
The Trump administration's funding cuts to PEPFAR and USAID disrupted global HIV treatment and prevention, threatening progress made over decades. Lenacapavir's FDA approval as a long-acting ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback